Immunocore Holdings plc

NASDAQ:IMCR

Biotechnology

Healthcare
$27.51 +0.63%

+$0.18 today

Market cap
$1.42B
Beta
0.75
P/E (TTM)
-77.5
EPS (TTM)
-$0.37
52W Low $27.56High $40.72

Volume 0.30M

Average 0.40M

IMCR Selling, General & Admin

Overhead costs of running the business, including sales, marketing, management, and administrative staff.

Immunocore Holdings plcNASDAQ: IMCR

Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026

Selling, general & admin declines year over year

Q1 FY2026 selling, general & admin of $37.85M fell 5.8% year over year, behind the -3.4% change in trailing-twelve-month selling, general & admin. Sequentially, it rose 22.2% from the prior quarter.

Context

  • Selling, general & admin amounted to 40.5% of revenue in FY2025, down 8.3 pp from a year earlier.
  • Selling, general & admin increased in 2 of the last 3 fiscal years.

What to watch

Whether selling, general & admin reaches the consensus estimate from 11 analysts of $404.13M (+235.0%) for the fiscal year ending Dec 2026, a step up from the -0.5% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
$37.85M+22.2% QoQ
Last fiscal yearDec 2025
$120.62M-0.5% YoY
LTMMar 2026
$151.41M-3.4% YoY
Selling, General & Admin past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-5.8%+132.6%+138.4 pp
1 year-0.5%+235.0%+235.5 pp
3-year CAGR—+63.0%—
5-year CAGR+51.0%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Selling, General & Admin history

Mixed currencies · from the income statement

Latest · FY2025
120.62M USD
Year-over-year change
-0.5%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Selling, General & Admin vs competitors

How IMCR compares with its peers on the latest reported figures

  • Peers report in different currencies, so selling, general & admin is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -3.4% is the 7th highest of 11, against a peer median of -1.7%.
  • Selling, general & admin amounts to 39.2% of revenue for IMCR, versus a peer median of 96.1%.
IMCR Competitors
Selling, General & Admin for IMCR and competitors
Company Period LTM YoY 3-year CAGR% of revenue
BNTXBioNTech SELTM Jun 2026€788.8M EUR+45.9%+8.9%29.8%
IBRXImmunityBio, Inc.LTM Sep 2026$185.41M USD+24.0%+12.7%101.6%
IMCRImmunocore Holdings plcLTM Mar 2026$151.41M USD-3.4%—39.2%
RCUSArcus Biosciences, Inc.LTM Jun 2026$106M USD-7.8%+1.9%90.6%
XNCRXencor, Inc.LTM Jun 2026$65.29M USD+5.1%+10.3%62.2%
IMTXImmatics N.V.LTM Mar 2026€53.63M EUR+14.4%+12.3%143.8%
JANXJanux Therapeutics, Inc.LTM Mar 2026$42.56M USD-1.1%+23.3%196.9%
MGNXMacroGenics, Inc.LTM Mar 2026$38.15M USD-27.9%-12.7%24.3%
IPHAInnate Pharma S.A.FY2025€11M EUR-7.8%-8.7%394.7%
CGENCompugen Ltd.LTM Mar 2026$9.36M USD-6.3%-5.7%12.9%
IMMPImmutep LimitedFY2025A$8.64M AUD-2.4%+6.2%171.4%
Peer median (excluding IMCR) —-1.7%+7.5%96.1%

Competitors are the stored peer set for IMCR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

Mixed currencies
Metric
FY2021
Dec 2021 · GBP
FY2022
Dec 2022 · GBP
FY2023
Dec 2023 · GBP
FY2024
Dec 2024 · USD
FY2025
Dec 2025 · USD
Revenue27.04M144.23M197.39M247.98M297.57M
Cost of Revenue05.29M820.63K5.54M6.21M
Gross Profit27.04M138.94M196.57M242.44M291.36M
Gross Margin100.0%96.3%99.6%97.8%97.9%
Research & Development74.31M84.31M129.42M177.44M204.47M
Selling, General & Admin82.15M0114.35M121.17M120.62M
Operating Expenses156.46M181.71M243.77M298.77M325.09M
Depreciation & Amortization5.63M4.41M3.24M3.36M2.43M
EBITDA(123.58M)(38.35M)(40.87M)(38.5M)387.18K
EBITDA Margin-457.0%-26.6%-20.7%-15.5%0.1%
Operating Income(129.42M)(42.77M)(47.2M)(56.28M)(33.74M)
Operating Margin-478.5%-29.7%-23.9%-22.7%-11.3%
Interest Income65K3.76M14.23M25.62M16.48M
Interest Expense5.57M5.41M4.08M18.84M12.17M
Other Income / Expenses(3.92M)8.95M(982.07K)14.01M19.53M
Income Before Tax(133.34M)(33.82M)(48.19M)(42.32M)(14.21M)
Pre-Tax Margin-493.0%-23.4%-24.4%-17.1%-4.8%
Income Tax Expense111.19K9.65M(4.43M)(1.48M)12.21M
Net Income(133.45M)(43.46M)(43.75M)(40.81M)(26.42M)
Net Margin-493.4%-30.1%-22.2%-16.5%-8.9%
EPS (Basic)(3.13)(0.95)(0.89)(1.02)(0.53)
EPS (Diluted)(3.00)(0.95)(0.89)(1.02)(0.53)
Weighted Avg Shares42.49M45.71M48.89M49.99M50.35M
Weighted Avg Shares (Diluted)43.86M45.71M48.89M49.99M50.35M

Immunocore Holdings plc

NASDAQ:IMCR

Intrinsic Alpha fair value

Locked

Current Price

$27.51

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.